Psychosocial Outcomes in Families of COVID-19 ICU Patients
Psychosocial Outcomes in Families of Patients Admitted in ICU for COVID-19 During the Pandemic in Belgium
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, 4000
- University Hospital of Liege
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- the referent family member of any patient admitted in ICU for COVID-19 during the first part of the pandemic
Exclusion Criteria:
- cognitive disorders
- not French-speaking
- refusal to participate
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
occurence of anxiety and depression
Time Frame: one month after ICU discharge
|
sub scores of HADS questionnaire >7
|
one month after ICU discharge
|
|
occurence of anxiety and depression
Time Frame: three months after ICU discharge
|
sub scores of HADS questionnaire >7
|
three months after ICU discharge
|
|
occurence of acute stress
Time Frame: one month after ICU discharge
|
IES-R score > 22
|
one month after ICU discharge
|
|
occurence of post-traumatic stress disorder
Time Frame: three months after ICU discharge
|
IES-R score > 36
|
three months after ICU discharge
|
|
quality of life
Time Frame: one month after ICU discharge
|
assessed using the EQ-5D questionnaire
|
one month after ICU discharge
|
|
quality of life
Time Frame: three months after ICU discharge
|
assessed using the EQ-5D questionnaire
|
three months after ICU discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- COVID-19
- Stress, Psychological
- Critical Illness
Other Study ID Numbers
Other Study ID Numbers
- Family COVID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.